Original Article
Influenza Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke among the Elderly
N Engl J Med 2003; 348:1322-1332April 3, 2003
- Abstract
Background
Upper respiratory tract illnesses have been associated with an increased risk of ischemic heart disease and stroke. During two influenza seasons, we assessed the influence of vaccination against influenza on the risk of hospitalization for heart disease and stroke, hospitalization for pneumonia and influenza, and death from all causes.
Methods
Cohorts of community-dwelling members of three large managed-care organizations who were at least 65 years old were studied during the 1998–1999 and 1999–2000 influenza seasons. Administrative and clinical data were used to evaluate outcomes, with multivariable logistic regression to control for base-line demographic and health characteristics of the subjects.
Results
There were 140,055 subjects in the 1998–1999 cohort and 146,328 in the 1999–2000 cohort, of which 55.5 percent and 59.7 percent, respectively, were immunized. At base line, vaccinated subjects were on average sicker, having higher rates of most coexisting conditions, outpatient care, and prior hospitalization for pneumonia than unvaccinated subjects. Unvaccinated subjects, however, were more likely to have been given a prior diagnosis of dementia or stroke. Vaccination against influenza was associated with a reduction in the risk of hospitalization for cardiac disease (reduction of 19 percent during both seasons [P<0.001]), cerebrovascular disease (reduction of 16 percent during the 1998–1999 season [P<0.018] and 23 percent during the 1999–2000 season [P<0.001]), and pneumonia or influenza (reduction of 32 percent during the 1998–1999 season [P<0.001] and 29 percent during the 1999–2000 season [P<0.001]) and a reduction in the risk of death from all causes (reduction of 48 percent during the 1998–1999 season [P<0.001] and 50 percent during the 1999–2000 season [P<0.001]). In analyses according to age, the presence or absence of major medical conditions at base line, and study site, the findings were consistent across all subgroups.
Conclusions
In the elderly, vaccination against influenza is associated with reductions in the risk of hospitalization for heart disease, cerebrovascular disease, and pneumonia or influenza as well as the risk of death from all causes during influenza seasons. These findings highlight the benefits of vaccination and support efforts to increase the rates of vaccination among the elderly.
Media in This Article
Figure 1
Effect of Vaccination against Influenza on the Odds Ratio for Hospitalization for Pneumonia or Influenza, Cardiac Causes, Cerebrovascular Causes, or Any Cause and the Odds Ratio for Death during the 1998–1999 Influenza Season, According to Age (Panel A), Risk (Panel B), and Study Site (Panel C).Table 1
Base-Line Characteristics of Subjects in the 1998–1999 and 1999–2000 Cohorts.Article Activity
- Article
Serious complications of influenza among the elderly include pneumonia and exacerbations of coexisting conditions that can result in hospitalization or death.1 Vaccination against influenza has consistently been associated with reductions in hospitalizations for pneumonia and death from all causes in the elderly.2,3
During influenza epidemics, hospitalizations for cerebrovascular and cardiovascular causes increase,4-8 and acute infections, including upper respiratory tract infections, may increase the risk of acute cardiovascular9-11 and cerebrovascular12-17 events. Several small observational studies have suggested that influenza vaccination may be associated with a reduction in the risk of cardiac arrest,18 myocardial infarction,19 and acute cerebrovascular events,20 although not all have found such a benefit.21 In a small, unblinded, controlled trial, vaccination was also associated with lower rates of death, myocardial infarction, or revascularization among persons with an acute coronary syndrome and those scheduled to undergo percutaneous coronary intervention.22 We studied two large cohorts during the 1998–1999 and 1999–2000 influenza seasons to assess whether influenza vaccination of community-dwelling elderly persons is associated with reduced rates of hospitalization for cardiac and cerebrovascular disease.
Methods
Setting
This is one of several studies involving the pooling of computerized data from three large managed-care organizations. Previously, we reported on the ability of vaccination against influenza to reduce the rates of hospitalization for pneumonia and influenza and death from all causes among the elderly members of these organizations23 and among elderly members with specific high-risk medical conditions24 during the 1996–1997 and 1997–1998 influenza seasons. The managed-care organizations are HealthPartners (650,000 members in Minnesota and Wisconsin), Oxford Health Plan (1.8 million members in New York, New Jersey, Pennsylvania, and Connecticut), and Kaiser Permanente Northwest (420,000 members in the Portland, Oregon–Vancouver, Washington area). This project was approved by the research-review boards of the health plans.
Subjects
Plan members who were at least 65 years of age on October 1, 1998 (for the 1998–1999 cohort), and October 1, 1999 (for the 1999–2000 cohort), were included in the study if they were not institutionalized and had been continuously enrolled during the preceding 12 months and throughout the outcome period. These criteria were used to ensure adequate base-line and outcome data on the subjects. In the case of the Oxford Health Plan, only members in the New York City area and adjacent counties were included, since data for the rest of the areas covered by the plan were incomplete. All elderly members of the other health plans were included.
Data Collection and Outcomes
Using uniform definitions, we obtained from the administrative and clinical data bases of each plan information on demographic characteristics (age, sex, and site); base-line coexisting conditions, defined by inpatient or outpatient diagnoses of heart disease (International Classification of Diseases, 9th Revision, Clinical Modification codes 093, 112.81, 130.3, 391, 393 through 398, 402, 404, 410 through 429, 745, 746, 747.1, 747.49, 759.82, 785.2, and 785.3), lung disease (codes 011, 460, 462, 465, 466, 480 through 511, 512.8, 513 through 517, 518.3, 518.8, 519.9, and 714.81), diabetes (codes 250 and 251), renal disease (codes 274.1, 408, 580 through 591, 593.71 through 593.73, and 593.9), cancer (codes 200 through 208, 140 through 198, and 199.1), vasculitis and rheumatologic disease (codes 446, 710, 714.0 through 714.4, 714.8, 714.89, and 714.9), dementia and stroke (codes 290 through 294, 331, 340, 341, 348, and 438), hypertension (code 401), atrial fibrillation (code 427.3), and lipid disorders (code 272); the number of outpatient visits during the base-line period; and the number of hospitalizations during the base-line period. The study outcomes included hospitalization for pneumonia or influenza (codes 480 through 487), acute cerebrovascular disease (codes 431 through 437), cardiac disease — ischemic heart disease (codes 410 through 414) and congestive heart failure (code 428) — and death from any cause. Influenza-vaccination status was also ascertained from the data bases, as defined by Current Procedural Terminology code 90657, and any site-specific flags in the clinical data bases.
Influenza Seasons
Influenza seasons were defined by the dates that the first and last influenza isolates were obtained in a region according to surveillance data reported to the Centers for Disease Control and Prevention. Outcomes were included if they occurred during an influenza season or within two weeks after its end in order to include delayed complications of influenza.
Statistical Analysis
Bivariable comparisons of the base-line characteristics of vaccinated and unvaccinated subjects were conducted using chi-square tests and Student's t-tests for categorical and continuous variables, respectively. Multivariable logistic regression (with SPSS 10.1 for Windows, SPSS) was used to compare the study outcomes between vaccinated and unvaccinated subjects after adjustment for base-line demographic characteristics, coexisting conditions, and previous use of health care. The subject's age (65 to 74, 75 to 84, or 85 years or older) and number of outpatient visits (12 or more vs. fewer than 12 [upper one third vs. lower two thirds]) were included as categorical variables in the regression models. We estimated vaccine effectiveness by subtracting the adjusted odds ratio from 1, using the adjusted odds ratio as an approximation of relative risk. We calculated the numbers needed to treat (i.e., vaccinate) to prevent one outcome25 using the following equation: 1 ÷ (vaccine effectiveness × the event rate in unvaccinated subjects). Analyses were conducted in subgroups according to age, risk (high risk, defined by one of the following coexisting conditions: heart disease, lung disease, diabetes or endocrine disorders, renal disease, stroke or dementia, vasculitis or rheumatologic disease, or cancer; and low risk, defined by the absence of any of these conditions), and site. Analyses involving a partial model (adjusted for demographic characteristics) and a complete model (adjusted for all the variables described above) were conducted to determine the effect of adjustment for covariates on the results.
To evaluate in more detail the adequacy of adjustment in the regression models, we assessed the effect of vaccination on the risk of hospitalization during the summer months after each influenza season (June through September 1999 and June through September 2000). This period was selected as a control period. We expected vaccination to provide minimal benefit then, because influenza was not circulating at those times. To account for life-expectancy bias we estimated the ability of vaccination to reduce the rate of hospitalization during the influenza seasons after excluding everyone who died during the outcome period.
Results
There were 140,055 subjects in the 1998–1999 cohort and 146,328 in the 1999–2000 cohort. The respective rates of vaccination against influenza were 55.5 percent and 59.7 percent. At base line, vaccinated subjects were older and had a greater overall burden of illness and higher rates of health care use (Table 1Table 1
Base-Line Characteristics of Subjects in the 1998–1999 and 1999–2000 Cohorts.). Unvaccinated subjects, however, were more likely to have been given a diagnosis of dementia or stroke. These trends persisted after adjustment for demographic characteristics (age, sex, and site) (Table 1). Both influenza seasons were characterized by the circulation of type A (H3N2) influenza viruses that were well matched to the corresponding strains included in the vaccine.26,27 During the 1998–1999 influenza season, there were 1677 and 1888 hospitalizations for study outcomes and 943 and 1361 deaths among vaccinated and unvaccinated subjects, respectively, and during the 1999–2000 influenza season, there were 1959 and 1574 hospitalizations for study outcomes and 1019 and 1026 deaths among vaccinated and unvaccinated subjects, respectively (Table 2Table 2
Outcomes during the Influenza Seasons among Vaccinated and Unvaccinated Subjects.). The rates of all outcomes were higher among unvaccinated subjects than among vaccinated subjects.The partial logistic-regression models included demographic characteristics (site, sex, and age, categorized as 65 to 74, 75 to 84, or 85 years or older) and vaccination status. The complete models included these variables in addition to the presence or absence at base line of various coexisting conditions (heart disease, lung disease, diabetes or endocrine disorders, cancer, renal disease, vasculitis or rheumatologic disease, dementia or stroke, hypertension, atrial fibrillation, and lipid disorders), health care use during the base-line period (12 or more outpatient visits vs. fewer than 12 outpatient visits), and the presence or absence of hospitalization for pneumonia or influenza.
Analyses involving the complete models showed that influenza vaccination in both cohorts was associated with reductions in the odds of all the study outcomes during the influenza seasons (Table 3Table 3
Effectiveness of Influenza Vaccination during the Influenza Seasons and Numbers Needed to Treat to Prevent One Outcome in the 1998–1999 and 1999–2000 Cohorts.), including hospitalization for cerebrovascular disease (reduction of 16 percent during the 1998–1999 season [P=0.018] and 23 percent during the 1999–2000 season [P<0.001]), cardiac disease (reduction of 19 percent during both seasons [P<0.001]), and pneumonia or influenza (reduction of 32 percent during the 1998–1999 season [P<0.001] and 29 percent during the 1999–2000 season [P<0.001]) and death from all causes (reduction of 48 percent during the 1998–1999 season [P<0.001] and 50 percent during the 1999–2000 season [P<0.001]). When the odds of hospitalization for ischemic heart disease and congestive heart failure were analyzed separately, the reductions were also significant in every case except that of ischemic heart disease during the 1999–2000 season (reduction, 10 percent; P=0.12). Estimates of vaccine effectiveness were generally consistent among the age subgroups (Figure 1AFigure 1Effect of Vaccination against Influenza on the Odds Ratio for Hospitalization for Pneumonia or Influenza, Cardiac Causes, Cerebrovascular Causes, or Any Cause and the Odds Ratio for Death during the 1998–1999 Influenza Season, According to Age (Panel A), Risk (Panel B), and Study Site (Panel C).), risk subgroups (Figure 1B), and site subgroups (Figure 1C) for both influenza seasons. For the combined outcome of hospitalization or death, the numbers needed to treat (i.e., vaccinate) to prevent one outcome were 61 in the 1998–1999 cohort and 68 in the 1999–2000 cohort (Table 3). Estimates of vaccine effectiveness were lower in the partial models and in some instances were 0 percent, highlighting the importance of the adjustment for coexisting conditions and health care use in the complete models (Table 3).Vaccination against influenza was not associated with significant reductions in the odds of hospitalization during the summer months. In our subgroup analyses, which excluded subjects who died, estimates of the ability of vaccination to reduce the risk of hospitalization during the two influenza seasons were virtually identical to those for the entire cohort in the two seasons (data not shown).
Discussion
In this observational study, influenza vaccination of elderly persons was associated with substantial reductions in the risk of hospitalization for cardiac disease and cerebrovascular disease during two influenza seasons. Several previous studies have suggested similar findings. In a population-based case–control study of 342 married persons who had had an out-of-hospital cardiac arrest but no other risk factors for cardiac disease, influenza vaccination during the previous 12 months was associated with a 49 percent reduction in the risk of cardiac arrest (odds ratio, 0.51; 95 percent confidence interval, 0.33 to 0.79).18 In another case–control study of 109 patients in a cardiology clinic who had a myocardial infarction during the 1997–1998 influenza season, vaccination against influenza was associated with a 67 percent reduction in the risk of a myocardial infarction as compared with control subjects, who had not had a myocardial infarction (odds ratio, 0.33; 95 percent confidence interval, 0.13 to 0.82).19 A case–control study of 90 patients who were 60 years of age or older and living in France and who were consecutively admitted with a stroke during the 1998–1999 and 1999–2000 influenza seasons and 180 controls found that influenza vaccination was associated with a 50 percent reduction in the risk of a stroke (odds ratio, 0.50; 95 percent confidence interval, 0.26 to 0.94).20
In addition to the observational studies, an unblinded, controlled trial of vaccination among 200 patients with acute myocardial infarction and 101 patients who were undergoing angioplasty or stent placement in Argentina found that vaccination was associated with a lower risk of death from cardiovascular causes (relative risk, 0.25; 95 percent confidence interval, 0.07 to 0.86) and of the combined end point of death, myocardial infarction, or revascularization (relative risk, 0.50; 95 percent confidence interval, 0.29 to 0.85).22 Our study extends these observations from previous studies by simultaneously assessing the risk of hospitalization for cerebrovascular disease and cardiac disease as well as the more commonly evaluated influenza-associated complications of hospitalization for pneumonia and death. Furthermore, we studied large cohorts that had many outcomes, thereby increasing the power of the study. We also included data from two influenza seasons and three geographically dispersed health care organizations, thus enhancing the generalizability of our findings to other seasons and settings.
Not all reports have found that influenza vaccination protects against cardiac disease. A cohort study of 1378 patients who survived a myocardial infarction between 1992 and 1996 found no evidence that vaccination protected against recurrent coronary events after 3267 person-years of follow-up.21 That study also evaluated members of health maintenance organizations, but the subjects differed from those in our study. About half were younger than 65 years of age, and all of them had survived a myocardial infarction. Certain risk factors may have a stronger influence on the risk of recurrent events among younger persons with cardiac disease than among older persons, thus making it difficult to detect benefits attributable to vaccination. Although the analytic models were similar in the two studies, the covariates included in the models were not identical, and this may also have contributed to the differences in results. In addition, the other study defined the outcome period as the six-month period from November through April. We used a more specific outcome period based on influenza-surveillance data, and this may have enhanced our ability to detect the effectiveness of vaccination. Finally, we had a larger cohort and included a broader spectrum of outcomes.
Possible mechanisms of the increased risk of cerebrovascular and cardiovascular events after upper respiratory tract illnesses such as influenza include alterations in circulating clotting factors, platelet aggregation and lysis, concentrations of inflammatory-response proteins, and alterations in cytokine concentrations.12,28 These changes might enhance thrombotic tendencies, impair vasodilation, or cause endothelial injury.
We identified vaccination-associated reductions in the risk of hospitalizations for pneumonia and influenza and death from all causes. Observational studies from various regions in the United States, Canada (Manitoba), the United Kingdom, Spain, Italy, and Argentina have also found that vaccination against influenza is associated with reductions in the risk of hospitalization for pneumonia or influenza of about 20 to 40 percent.29-38 In our study, vaccination was associated with a reduction in the risk of hospitalization for pneumonia or influenza of 29 to 32 percent.
Observational studies from the United States, Manitoba, and the United Kingdom have reported that influenza vaccination is associated with reductions in the risk of death from any cause of 30 to 50 percent.23,32,33,39 In our study, vaccination was associated with a reduction in the risk of death from all causes of 48 to 50 percent. This reduction may be greater than might typically be expected. Hospitalization for pneumonia and exacerbations of underlying medical conditions are well-recognized complications of influenza. Our finding that vaccination is associated with reductions in the risk of hospitalization for cardiac and cerebrovascular disease suggests additional effects of influenza that contribute to the overall disease burden and may help to explain the reduction in the risk of death associated with vaccination.
The elderly, as well as persons younger than 65 years of age who have high-risk medical conditions, are included in the high-priority groups targeted for vaccination.1 Influenza vaccination is similarly effective in reducing the risk of hospitalization for pneumonia or death in healthy elderly persons and in those with coexisting conditions.24,32 We found that vaccination reduced the risk of hospitalization for cardiac and cerebrovascular causes in a similar manner among both healthy and high-risk elderly persons. Many persons with high-risk medical conditions receive care from subspecialty physicians. Subspecialists, however, are less likely than generalists to recommend influenza vaccination to their high-risk patients.40 Both generalists and medical subspecialists should recommend influenza vaccinations to their elderly and high-risk patients.
Our study has several potential limitations, and the results should be interpreted with caution. Because this was an observational study, we included important covariates in the analytic models. We also conducted subgroup analyses to identify possible interactions or bias in the results. Nevertheless, residual confounding may have influenced our results. Misclassification of study data, including vaccination status, is another concern. However, at one of our health plan sites, more than 90 percent of high-risk members who were vaccinated received the vaccine at a health plan site.41 Furthermore, agreement between medical records and computerized data bases has been excellent, with more than 95 percent agreement at two of the study sites.23-25 Even if substantial misclassification occurred, it would most likely bias the study toward negative results.
We did not collect information on pneumococcal vaccination status for the study. In contrast to influenza vaccinations, which require annual administration, pneumococcal vaccinations are usually given only once and may be effective for 6 to 10 years. We were unable to obtain the data for the prior 6 to 10 years that would be needed to characterize pneumococcal-vaccination status accurately. Pneumococcal vaccination reduces the risk of bacteremic disease but has not consistently been shown to reduce the risk of hospitalization for pneumonia.42 In one study that used analytic models similar to ours, the 12-month pneumococcal-vaccination status was not a significant variable.43 In another study, pneumococcal vaccination was not associated with a reduction in the risk of recurrent coronary events.21 Nevertheless, if pneumococcal vaccination significantly reduces the risk of any of our study outcomes, then some of the benefits attributed to influenza vaccination may actually have been due to pneumococcal vaccination.
Influenza-associated deaths in the United States have increased significantly over the past two decades, with 90 percent occurring among the elderly.44 In 2001, the rate of vaccination against influenza was only 63 percent among persons 65 years of age or older in the United States45 — well below the 2010 goal of 90 percent.46 Our findings highlight the benefits to be realized with vaccination and lend urgency to efforts to improve the rate of vaccination among the elderly.
Supported by the National Vaccine Program Office and the Centers for Disease Control and Prevention through an agreement with the American Association of Health Plans.
Source Information
From the Veterans Affairs Medical Center and the University of Minnesota, Minneapolis (K.L.N.); HealthPartners Research Foundation, Minneapolis (J.N., K.F.); Kaiser Permanente Northwest, Portland, Oreg. (J.M.); Oxford Health Plan, New York (R.L.); and the Centers for Disease Control and Prevention, Atlanta (M.I.).
Address reprint requests to Dr. Nichol at the Veterans Affairs Medical Center (111), 1 Veterans Dr., Minneapolis, MN 55417, or at nicho014@umn.edu.
- References
References
1
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002;51:1-31
Medline2
Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of influenza. Oxford, England: Blackwell Science, 1998:358-72.
3
Vu T ,Farish S ,Jenkins M ,Kelly H . A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-1836
CrossRef | Web of Science | Medline4
Collins SD . Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Rep 1932;47:2159-2179
CrossRef | Medline5
Eickhoff TC ,Sherman IL ,Serfling RE . Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776-782
Web of Science | Medline6
Housworth J ,Langmuir AD . Excess mortality from epidemic influenza, 1957-1966. Am J Epidemiol 1974;100:40-48
Web of Science | Medline7
Alling DW ,Blackwelder WC ,Stuart-Harris CH . A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1981;113:30-43
Web of Science | Medline8
Bainton D ,Jones GR ,Hole D . Influenza and ischemic heart disease -- a possible trigger for acute myocardial infarction? Int J Epidemiol 1978;7:231-239
CrossRef | Web of Science | Medline9
Spodick DH ,Flessas AP ,Johnson MM . Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol 1984;53:481-482
CrossRef | Web of Science | Medline10
Mattila KJ . Viral and bacterial infections in patients with acute myocardial infarction. J Intern Med 1989;225:293-296
CrossRef | Web of Science | Medline11
Meier CR ,Jick SS ,Derby LE ,Vasilakis C ,Jick H . Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998;351:1467-1471
CrossRef | Web of Science | Medline12
Valtonen VV . Infection as a risk factor for infarction and atherosclerosis. Ann Intern Med 1991;23:539-543
Web of Science13
Syrjanen J ,Valtonen VV ,Iivanainen M ,Kaste M ,Huttunen JK . Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed) 1988;296:1156-1160
CrossRef | Web of Science | Medline14
Bova IY ,Bornstein NM ,Korczyn AD . Acute infection as a risk factor for ischemic stroke. Stroke 1996;27:2204-2206
CrossRef | Web of Science | Medline15
Becher H ,Grau A ,Steindorf K ,Buggle F ,Hacke W . Previous infection and other risk factors for acute cerebrovascular ischaemia: attributable risks and the characterisation of high risk groups. J Epidemiol Biostat 2000;5:277-283
Medline16
Jakovljevic D ,Salomaa V ,Sivenius J , et al. Seasonal variation in the occurrence of stroke in a Finnish adult population: the FINMONICA Stroke Register: Finnish Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 1996;27:1774-1779
CrossRef | Web of Science | Medline17
Macko RF ,Ameriso SF ,Barndt R ,Clough W ,Weiner JM ,Fisher M . Precipitants of brain infarction: roles of preceding infection/inflammation and recent psychological stress. Stroke 1996;27:1999-2004
CrossRef | Web of Science | Medline18
Siscovick DS ,Raghunathan RE ,Lin D , et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000;152:674-677
CrossRef | Web of Science | Medline19
Naghavi M ,Barlas Z ,Siadaty S ,Naguib S ,Madjid M ,Casscells W . Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000;102:3039-3045
Web of Science | Medline20
Lavallee P ,Perchaud V ,Gautier-Bertrand M ,Grabli D ,Amarenco P . Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002;33:513-518[Erratum, Stroke 2002;33:1171.]
CrossRef | Web of Science | Medline21
Jackson LA ,Yu O ,Heckbert SR , at al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 2002;156:634-640
CrossRef | Web of Science | Medline22
Gurfinkel EP ,de la Fuente L ,Mendiz O ,Mautner B . Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002;105:2143-2147
CrossRef | Web of Science | Medline23
Nordin J ,Mullooly J ,Poblete S , et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665-670
CrossRef | Web of Science | Medline24
Hak E ,Nordin J ,Wei F , et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002;35:370-377
CrossRef | Web of Science | Medline25
Cook RJ ,Sackett DL . The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-454[Erratum, BMJ 1995;310:1056.]
CrossRef | Web of Science | Medline26
Update: influenza activity -- United States and worldwide, 1998-99 season, and composition of the 1999-2000 influenza vaccine. MMWR Morb Mortal Wkly Rep 1999;48:374-378
Medline27
Update: influenza activity -- United States and worldwide, 1999-2000 season, and composition of the 2000-01 influenza vaccine. MMWR Morb Mortal Wkly Rep 2000;49:375-381
Medline28
Epstein SE ,Zhou YF ,Shu J . Infection and atherosclerosis: emerging mechanistic paradigms. Circulation 1999;100:e20-e28
Web of Science | Medline29
Mullooly JP ,Bennett MD ,Hornbrook MC , et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-952
Web of Science | Medline30
Foster DA ,Talsma A ,Furumoto-Dawson A , et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307
Web of Science | Medline31
Ohmit SE ,Monto AS . Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995;24:1240-1248
CrossRef | Web of Science | Medline32
Nichol KL ,Wuorenma J ,von Sternberg T . Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-1776
CrossRef | Web of Science | Medline33
Fedson DS ,Wajda A ,Nichol JP ,Hammond GW ,Kaiser DL ,Roos LL . Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270:1956-1961[Erratum, JAMA 1994;271:1578.]
CrossRef | Web of Science | Medline34
Ahmed AH ,Nicholson KG ,Nguyen-van Tam JS ,Pearson JC . Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic. Epidemiol Infect 1997;118:27-33
CrossRef | Web of Science | Medline35
Fleming DM ,Watson JM ,Nicholas S ,Smith GE ,Swan AV . Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect 1995;115:581-589
CrossRef | Web of Science | Medline36
Puig-Barbera J ,Marquez-Calderon S ,Masoliver-Fores A , et al. Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. J Epidemiol Community Health 1997;51:526-530
CrossRef | Web of Science | Medline37
Crocetti E ,Arniani S ,Bordoni F ,Maciocco G ,Zappa M ,Buiatti E . Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J Epidemiol 2001;17:163-168
CrossRef | Web of Science | Medline38
Stamboulian D ,Bonvehi PE ,Nacinovich FM ,Ruttimann RW . Immunization against influenza in the elderly: the Argentinian experience, 1993-1997. Vaccine 1999;17:Suppl 1:S53-S56
CrossRef | Web of Science | Medline39
Ahmed AEH ,Nicholson KG ,Nguyen-Van-Tam JS . Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995;346:591-595
CrossRef | Web of Science | Medline40
Nichol KL ,Zimmerman R . Generalist and subspecialist physicians' knowledge, attitudes, and practices regarding influenza and pneumococcal vaccinations for elderly and other high-risk patients: a nationwide survey. Arch Intern Med 2001;161:2702-2708
CrossRef | Web of Science | Medline41
Mac Donald R ,Baken L ,Nelson A ,Nichol KL . Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med 1999;16:173-177
CrossRef | Web of Science | Medline42
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-24
Medline43
Nichol KL ,Margolis KL ,Wuorenma J ,Von Sternberg T . The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784
Full Text | Web of Science | Medline44
Thompson WW ,Shay DK ,Weintraub E , et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186
CrossRef | Web of Science | Medline45
Early release of selected estimates from the National Health Interview Survey (NHIS): data from January-June 2001. Atlanta: Centers for Disease Control and Prevention, 2002. (Accessed February 4, 2003, at http://www.cdc.gov/nchs/nhis.htm.)
46
Healthy People 2010: conference edition. Vol. 1. Washington, D.C.: Department of Health and Human Services, January 2000.
- Citing Articles (190)
Citing Articles
1
Janet E. McElhaney, Xin Zhou, H. Keipp Talbot, Ernst Soethout, R. Chris Bleackley, David Granville, Graham Pawelec. (2012) The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine
CrossRef2
A. Rodríguez, L. Álvarez-Rocha, J.M. Sirvent, R. Zaragoza, M. Nieto, A. Arenzana, P. Luque, L. Socías, M. Martín, D. Navarro, J. Camarena, L. Lorente, S. Trefler, L. Vidaur, J. Solé-Violán, F. Barcenilla, A. Pobo, J. Vallés, C. Ferri, I. Martín-Loeches, E. Díaz, D. López, M.J. López-Pueyo, F. Gordo, F. del Nogal, A. Marqués, S. Tormo, M.P. Fuset, F. Pérez, J. Bonastre, B. Suberviola, E. Navas, C. León. (2012) Recomendaciones del Grupo de Trabajo Enfermedades Infecciosas (GTEI) de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) y el Grupo de Estudio de Infecciones en el Paciente Crítico (GEIPC) de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica (SEIMC) para el diagnóstico y tratamiento de la gripe A/H1N1 en pacientes adultos graves hospitalizados en las Unidades de Cuidados Intensivos. Medicina Intensiva
CrossRef3
Jessica Chubak, Gaia Pocobelli, Noel S. Weiss. (2011) Tradeoffs between accuracy measures for electronic health care data algorithms. Journal of Clinical Epidemiology
CrossRef4
J. M. Ferdinands, D. K. Shay. (2011) Magnitude of Potential Biases in a Simulated Case-Control Study of the Effectiveness of Influenza Vaccination. Clinical Infectious Diseases
CrossRef5
Weiping Cao, Jin Hyang Kim, Tatiana Chirkova, Adrian J Reber, Renata Biber, David K Shay, Suryaprakash Sambhara. (2011) Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Review of Vaccines 10:11, 1529-1537
CrossRef6
Young June Choe, Heeyeon Cho, Sung Nam Kim, Geun-Ryang Bae, Jong-Koo Lee. (2011) Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003–2010. Vaccine 29:44, 7727-7732
CrossRef7
Amy J.H. Kind, Carolyn T. Thorpe, Justin A. Sattin, Stacy E. Walz, Maureen A. Smith. (2011) Provider Characteristics, Clinical-Work Processes and Their Relationship to Discharge Summary Quality for Sub-Acute Care Patients. Journal of General Internal Medicine
CrossRef8
Yi Li, Tiekuan Du, Matthew R. Lewin, Houli Wang, Xu Ji, Yanping Zhang, Tengda Xu, Lingjie Xu, Jack S. Wu. (2011) The seasonality of acute coronary syndrome and its relations with climatic parameters. The American Journal of Emergency Medicine 29:7, 768-774
CrossRef9
P. M. SMIT, S. VELDHUIS, J. W. MULDER, C. ROGGEVEEN, G. F. RIMMELZWAAN, J. C. M. MEIJERS, J. H. BEIJNEN, D. P. M. BRANDJES. (2011) Influenza vaccination and hemostasis: no sustainable procoagulant effects from 2009 H1N1 influenza vaccine in healthy healthcare workers. Journal of Thrombosis and Haemostasis 9:8, 1659-1661
CrossRef10
Janet E. McElhaney. (2011) Influenza vaccine responses in older adults. Ageing Research Reviews 10:3, 379-388
CrossRef11
L. Finelli, S. S. Chaves. (2011) Influenza and Acute Myocardial Infarction. Journal of Infectious Diseases 203:12, 1701-1704
CrossRef12
Marin H. Kollef. (2011) Prevention of Nosocomial Pneumonia in the Intensive Care Unit: Beyond the Use of Bundles. Surgical Infections 12:3, 211-220
CrossRef13
J. Tomas, F. Lelièvre, P. Bercelli, P.-Y. Glanddier, S. Fanello, F. Tuffreau, A. Tallec. (2011) Hospital admissions related to influenza in France during the 2006/2007 epidemic. Revue d'Épidémiologie et de Santé Publique 59:3, 159-167
CrossRef14
Lang Kau, Cheryl A. Sadowski, Christine Hughes. (2011) Vaccinations in older adults: Focus on pneumococcal, influenza and herpes zoster infections. Canadian Pharmacists Journal 144:3, 132-141
CrossRef15
Pedro Gil Gregorio, Jaime Rodríguez Salazar, Primitivo Ramos Cordero, José Gutiérrez Rodríguez, Carlos Rodríguez Pascual, José Antonio López Trigo, Norberto Moreno, Ramón Cisterna Cáncer, Luis Salleras Sanmartí, Juan González Armengol, José Antonio Forcadas Segarra. (2011) Recomendaciones de vacunación para adultos mayores de 60 años. Vacunas 12:2, 56-67
CrossRef16
Bradford D Gessner, Nahoko Shindo, Sylvie Briand. (2011) Seasonal influenza epidemiology in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 11:3, 223-235
CrossRef17
Gloria Mato Chaín, Alberto Mariano Lázaro, Florentina Alcudia Pérez, Carlos Verdejo Bravo. (2011) Vacunación antigripal en personas mayores. Revista Española de Geriatría y Gerontología 46:2, 89-95
CrossRef18
Antoine Nougairède, Rémi N. Charrel, Didier Raoult. (2011) Models cannot predict future outbreaks: A/H1N1 virus, the paradigm. European Journal of Epidemiology 26:3, 183-186
CrossRef19
Amy Kind, Paul Anderson, Jacqueline Hind, JoAnne Robbins, Maureen Smith. (2011) Omission of Dysphagia Therapies in Hospital Discharge Communications. Dysphagia 26:1, 49-61
CrossRef20
Valentina Parodi, Daniela de Florentiis, Mariano Martini, Filippo Ansaldi. (2011) Inactivated Influenza Vaccines. Drugs & Aging 28:2, 93-106
CrossRef21
Stella M. Gwini, Carol A.C. Coupland, Aloysius N. Siriwardena. (2011) The effect of influenza vaccination on risk of acute myocardial infarction: Self-controlled case-series study. Vaccine 29:6, 1145-1149
CrossRef22
Sae Yoon Kee, Hee Jin Cheong, Byung Chul Chun, Woo Joo Kim. (2011) Influenza Vaccination Coverage Rate and Factors Associated with Vaccination in People with Chronic Disease. Infection and Chemotherapy 43:5, 406
CrossRef23
Adam Denes, Emmanuel Pinteaux, Nancy J. Rothwell, Stuart M. Allan. (2011) Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic Target. Cerebrovascular Diseases 32:6, 517-527
CrossRef24
Ahmed B. Hashim, Tricia McKeever, Shona J. Kelly, Jonathan S. Nguyen-Van-Tam. (2010) Evaluation of inter-pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors. Journal of Infection and Public Health 3:4, 159-165
CrossRef25
Armin J. Grau, Christian Urbanek, Frederick Palm. (2010) Common infections and the risk of stroke. Nature Reviews Neurology 6:12, 681-694
CrossRef26
Kathy Hebert, George Marzouka, Lee Arcement, Elyse Julian, Frank Cortazar, Andre Dias, Leonardo Tamariz. (2010) Prevalence of Vaccination Rates in Systolic Heart Failure: A Prospective Study of 549 Patients by Age, Race, Ethnicity, and Sex in a Heart Failure Disease Management Program. Congestive Heart Failure 16:6, 278-283
CrossRef27
Xiu Ru Guan, Li Xin Jiang, Xue Hua Ma, Lan Feng Wang, Hude Quan, Hong Yuan Li. (2010) Respiratory Syncytial Virus Infection and Risk of Acute Myocardial Infarction. The American Journal of the Medical Sciences 340:5, 356-359
CrossRef28
Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
CrossRef29
Roger Baxter, G. Thomas Ray, Bruce H. Fireman. (2010) Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 28:45, 7267-7272
CrossRef30
Emilia Anis, Alex Leventhal, Paul E Slater, Yael Arbeli, Yoram Sivan, Yitzhak Berlovitz, Boaz Lev, Avi Israeli. (2010) A cluster of deaths following influenza vaccination, Israel, 2006. Journal of Public Health Policy 31:3, 318-323
CrossRef31
D. M. FLEMING, N. Q. VERLANDER, A. J. ELLIOT, H. ZHAO, D. GELB, D. JEHRING, J. S. NGUYEN-VAN-TAM. (2010) An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006. Epidemiology and Infection 138:09, 1281-1288
CrossRef32
Lee E. Morrow, Marin H. Kollef. (2010) Recognition and prevention of nosocomial pneumonia in the intensive care unit and infection control in mechanical ventilation. Critical Care Medicine 38, S352-S362
CrossRef33
Anant MOHAN, Subhash CHANDRA, Dipti AGARWAL, Randeep GULERIA, Shobha BROOR, Bharti GAUR, Ravindra Mohan PANDEY. (2010) Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology 15:3, 536-542
CrossRef34
Stefania Maggi. (2010) Vaccination and healthy aging. Expert Review of Vaccines 9:3s, 3-6
CrossRef35
Bruce Ovbiagele. (2010) Pathways to Further Boost Treatment Rates and Clinical Outcomes in Hospitalized Stroke Patients. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:1, 8-13
CrossRef36
Tom Jefferson, Carlo Di Pietrantonj, Lubna A Al-Ansary, Eliana Ferroni, Sarah Thorning, Roger E Thomas, Tom Jefferson. 2010. Vaccines for preventing influenza in the elderly. .
CrossRef37
Mark A. Moyad, Larry E. Robinson, Edward T. Zawada, Julie Kittelsrud, Ding-Geng Chen, Stuart G. Reeves, Susan Weaver. (2010) Immunogenic Yeast-Based Fermentate for Cold/Flu-like Symptoms in Nonvaccinated Individuals. The Journal of Alternative and Complementary Medicine 16:2, 213-218
CrossRef38
Vicente F Corrales-Medina, Mohammad Madjid, Daniel M Musher. (2010) Role of acute infection in triggering acute coronary syndromes. The Lancet Infectious Diseases 10:2, 83-92
CrossRef39
Anna M. Lundberg, Göran K. Hansson. (2010) Innate immune signals in atherosclerosis. Clinical Immunology 134:1, 5-24
CrossRef40
A. Pop-Vicas, S. Gravenstein. (2010) Influenza in the Elderly – A Mini-Review. Gerontology
CrossRef41
Viktorija Ķēniņa, Pauls Auce, Zanda Priede, Inese Irbe, Lana Vainšteina, Elvīra Smeltere, Andrejs Millers. (2010) Cytomegalovirus chronic infection as a risk factor for stroke: a prospective study. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 64:3, 133-136
CrossRef42
Orly Vardeny, John J. M Moran, Nancy K Sweitzer, Maryl R Johnson, Mary S Hayney. (2010) Decreased T-Cell Responses to Influenza Vaccination in Patients with Heart Failure. Pharmacotherapy 30:1, 10-16
CrossRef43
Mehran Haidari, Philip R. Wyde, Silvio Litovsky, Deborah Vela, Muzammil Ali, S. Ward Casscells, Mohammad Madjid. (2010) Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis 208:1, 90-96
CrossRef44
Tom Jefferson, Chris Del Mar, Liz Dooley, Eliana Ferroni, Lubna A Al-Ansary, Ghada A Bawazeer, Mieke L van Driel, Sreekumaran Nair, Ruth Foxlee, Alessandro Rivetti. 2010. .
CrossRef45
Hiroshi Kikuchi, Satoshi Kawasaki, Hitoshi Nakayama, Noriko Saito, Hisaki Shimada, Shigeru Miyazaki, Shinji Sakai, Masashi Suzuki. (2010) Efficacy and safety of oseltamivir in treatment and prevention of influenza virus infection in patients with hemodialysis. Nihon Toseki Igakkai Zasshi 43:5, 461-466
CrossRef46
W.A. Keitel, J.J. Treanor, H.M. El Sahly, A. Gilbert, A.L. Meyer, P.A. Patriarca, M.M. Cox. (2009) Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine 28:2, 379-385
CrossRef47
Walter S. Bartynski, Ameet R. Upadhyaya, John F. Boardman. (2009) Posterior Reversible Encephalopathy Syndrome and Cerebral Vasculopathy Associated With Influenza A Infection. Journal of Computer Assisted Tomography 33:6, 917-922
CrossRef48
Vivian Cristine Luft, Camila Giugliani, Erno Harzheim, Maria Inês Schmidt, Bruce Bartholow Duncan. (2009) Prevalence of use and potential impact of increased use of primary care interventions to prevent cardiovascular hospitalizations in patients with diabetes. Diabetes Research and Clinical Practice 85:3, 328-334
CrossRef49
B. Fireman, J. Lee, N. Lewis, O. Bembom, M. van der Laan, R. Baxter. (2009) Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias. American Journal of Epidemiology 170:5, 650-656
CrossRef50
Yu Tai, Ta-Chung Lee, Hsiao-Ling Chang, Kow-Tong Chen. (2009) Epidemiology and outcomes of hospitalization of influenza in the cancer population in Taiwan. Journal of Cancer Research and Clinical Oncology 135:8, 1061-1066
CrossRef51
Bevanne Bean-Mayberry, Elizabeth M. Yano, Maria K. Mor, Nichole K. Bayliss, Xiangyan Xu, Michael J. Fine. (2009) Does Sex Influence Immunization Status for Influenza and Pneumonia in Older Veterans?. Journal of the American Geriatrics Society 57:8, 1427-1432
CrossRef52
Arnold S. Monto, Filippo Ansaldi, Richard Aspinall, Janet E. McElhaney, Luis F. Montaño, Kristin L. Nichol, Joan Puig-Barberà, Joe Schmitt, Iain Stephenson. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:37, 5043-5053
CrossRef53
Patricia S. Keenan, Marc N. Elliott, Paul D. Cleary, Alan M. Zaslavsky, Bruce E. Landon. (2009) Quality Assessments by Sick and Healthy Beneficiaries in Traditional Medicare and Medicare Managed Care. Medical Care 47:8, 882-888
CrossRef54
J. R. Ward, H. L. Wilson, S. E. Francis, D. C. Crossman, I. Sabroe. (2009) Translational Mini-Review Series on Immunology of Vascular Disease: Inflammation, infections and Toll-like receptors in cardiovascular disease. Clinical & Experimental Immunology 156:3, 386-394
CrossRef55
Jean J. Schensul, Kim Radda, Emil Coman, Elsie Vazquez. (2009) Multi-Level Intervention to Prevent Influenza Infections in Older Low Income and Minority Adults. American Journal of Community Psychology 43:3-4, 313-329
CrossRef56
Alison Rue-Cover, John Iskander, Shauna Lyn, Dale R. Burwen, Paul Gargiullo, Sean Shadomy, Joel Blostein, Carolyn B. Bridges, Penina Haber, R. Duane Satzger, Robert Ball, Jane F. Seward. (2009) Death and serious illness following influenza vaccination: a multidisciplinary investigation. Pharmacoepidemiology and Drug Safety 18:6, 504-511
CrossRef57
Orly Vardeny, Nancy K. Sweitzer, Michelle A. Detry, John M. Moran, Maryl R. Johnson, Mary S. Hayney. (2009) Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. Journal of Cardiac Failure 15:4, 368-373
CrossRef58
Janet E McElhaney. (2009) Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Review of Vaccines 8:5, 593-606
CrossRef59
Jason V Baker, W Keith Henry, James D Neaton. (2009) The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Current Opinion in HIV and AIDS 4:3, 176-182
CrossRef60
De-chu C Tang, Jianfeng Zhang, Haroldo Toro, Zhongkai Shi, Kent R Van Kampen. (2009) Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Review of Vaccines 8:4, 469-481
CrossRef61
M.D.M. Assink, J.P. Kiewiet, M.H. Rozenbaum, P.B. Van den Berg, E. Hak, E.J. Buskens, J.C. Wilschut, A.C.M. Kroes, M.J. Postma. (2009) Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination. Vaccine 27:7, 1119-1126
CrossRef62
Hanne Støre Valeur, Guro Valen. (2009) Innate immunity and myocardial adaptation to ischemia. Basic Research in Cardiology 104:1, 22-32
CrossRef63
S. Wicker, H. F. Rabenau, H. W. Doerr, R. Allwinn. (2008) Influenza Vaccination Compliance Among Health Care Workers in a German University Hospital. Infection
CrossRef64
(2008) Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Española de Cardiología 61:12, 1329.e1-1329.e70
CrossRef65
Janet E McElhaney. (2008) Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines. Aging Health 4:6, 603-613
CrossRef66
Hoang Lai, Wilbert S Aronow, Andrew H Gutwein. (2008) Prevalence of Influenza Vaccination and Pneumococcal Vaccination in Elderly and High-Risk Patients Seen in a University General Medicine Clinic. American Journal of Therapeutics 15:6, 528-530
CrossRef67
Megumi Hara, Tatsuhiko Sakamoto, Keitaro Tanaka. (2008) Influenza vaccine effectiveness among elderly persons living in the community during the 2003–2004 season. Vaccine 26:50, 6477-6480
CrossRef68
Mamas Andreas Mamas, Doug Fraser, Ludwig Neyses. (2008) Cardiovascular manifestations associated with influenza virus infection. International Journal of Cardiology 130:3, 304-309
CrossRef69
Melanie Saville, Grenville Marsh, Agnes Hoffenbach. (2008) Improving seasonal and pandemic influenza vaccines. Influenza and Other Respiratory Viruses 2:6, 229-235
CrossRef70
Elizabeth Riley, Vijaya Dasari, William H. Frishman, Kirk Sperber. (2008) Vaccines in Development to Prevent and Treat Atherosclerotic Disease. Cardiology in Review 16:6, 288-300
CrossRef71
, K. Dickstein, A. Cohen-Solal, G. Filippatos, J. J.V. McMurray, P. Ponikowski, P. A. Poole-Wilson, A. Stromberg, D. J. van Veldhuisen, D. Atar, A. W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S. G. Priori, K. Swedberg, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , M. Tendera, A. Auricchio, J. Bax, M. Bohm, U. Corra, P. della Bella, P. M. Elliott, F. Follath, M. Gheorghiade, Y. Hasin, A. Hernborg, T. Jaarsma, M. Komajda, R. Kornowski, M. Piepoli, B. Prendergast, L. Tavazzi, J.-L. Vachiery, F. W. A. Verheugt, J. L. Zamorano, F. Zannad. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 29:19, 2388-2442
CrossRef72
Angelique G.S.C. Jansen, Elisabeth A.M. Sanders, Kristin L. Nichol, Anton M. van Loon, Arno W. Hoes, Eelko Hak. (2008) Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program. Vaccine 26:44, 5567-5574
CrossRef73
David Holland, Robert Booy, Ferdinandus De Looze, Peter Eizenberg, James McDonald, Jeff Karrasch, Maureen McKeirnan, Hatem Salem, Graham Mills, Jim Reid, Françoise Weber, Melanie Saville. (2008) Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial. The Journal of Infectious Diseases 198:5, 650-658
CrossRef74
Michael L Jackson, Jennifer C Nelson, Noel S Weiss, Kathleen M Neuzil, William Barlow, Lisa A Jackson. (2008) Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. The Lancet 372:9636, 398-405
CrossRef75
Xiu-Ru Guan, Xin Li, Xiao-Min Xin, Li-Xin Jiang, Lan-Ying Cui, Lan-Feng Wang, Hong-Yuan Li. (2008) Influenza Virus Infection and Risk of Acute Myocardial Infarction. Inflammation 31:4, 266-272
CrossRef76
Andrzej Ciszewski. (2008) Why young healthy adults should become a target group for the influenza vaccination: A cardiologist's point of view. Vaccine 26:35, 4411-4412
CrossRef77
Tymen Keller, Viola B Weeda, Carlo J van Dongen, Marcel Levi, Tymen Keller. 2008. Influenza vaccines for preventing coronary heart disease. .
CrossRef78
Julio Ramirez, Stefano Aliberti, Mehdi Mirsaeidi, Paula Peyrani, Giovanni Filardo, Asad Amir, Bryan Moffett, Josh Gordon, Francesco Blasi, Jose Bordon. (2008) Acute Myocardial Infarction in Hospitalized Patients with Community‐Acquired Pneumonia. Clinical Infectious Diseases 47:2, 182-187
CrossRef79
Marcie S. Rubin, Beth Nivin, Joel Ackelsberg. (2008) Effect of Timing of Amantadine Chemoprophylaxis on Severity of Outbreaks of Influenza A in Adult Long‐Term Care Facilities. Clinical Infectious Diseases 47:1, 47-52
CrossRef80
Daniel R. Martin, Mark E. Brauner, Joseph F. Plouffe. (2008) Influenza and Pneumococcal Vaccinations in the Emergency Department. Emergency Medicine Clinics of North America 26:2, 549-570
CrossRef81
Benjamin P. Best. (2008) Scientific Justification of Cryonics Practice. Rejuvenation Research 11:2, 493-503
CrossRef82
Félix Gutiérrez, Mar Masiá. (2008) Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia. Drugs & Aging 25:7, 585-610
CrossRef83
Lisa A Prosser, Megan A O’Brien, Noelle-Angelique M Molinari, Katherine H Hohman, Kristin L Nichol, Mark L Messonnier, Tracy A Lieu. (2008) Non-Traditional Settings for Influenza Vaccination of Adults. PharmacoEconomics 26:2, 163-178
CrossRef84
Ehud S. Kokia, Barbara G. Silverman, Manfred Green, Hagai Kedem, Michal Guindy, Joshua Shemer. (2007) Deaths following influenza vaccination—background mortality or causal connection?. Vaccine 25:51, 8557-8561
CrossRef85
Sabine Arnoux, Clement Weinberger, Bradford D. Gessner. (2007) Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip – an inactivated split virion influenza vaccine – supports wider vaccine use. Vaccine 25:45, 7720-7731
CrossRef86
U. Müller-Werdan, M. Meisel, P. Schirdewahn, K. Werdan. (2007) Ältere Patienten mit kardiovaskulären Erkrankungen. Der Internist 48:11, 1211-1219
CrossRef87
R.E. Jordan, J.I. Hawker, J.G. Ayres, W. Tunnicliffe, P. Adab, B. Olowokure, J. Kai, R.J. McManus, R. Salter, K.K. Cheng. (2007) A case–control study of elderly patients with acute respiratory illness: Effect of influenza vaccination on admission to hospital in winter 2003–2004. Vaccine 25:46, 7909-7913
CrossRef88
Nichol, Kristin L., Nordin, James D., Nelson, David B., Mullooly, John P., Hak, Eelko, . (2007) Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly. New England Journal of Medicine 357:14, 1373-1381
Full Text89
Treanor, John D., . (2007) Influenza — The Goal of Control. New England Journal of Medicine 357:14, 1439-1441
Full Text90
U. Müller-Werdan. (2007) Inflammation and ageing. Zeitschrift für Gerontologie und Geriatrie 40:5, 362-365
CrossRef91
Yvonne Schoefer, Tom Schaberg, Heiner Raspe, Torsten Schaefer. (2007) Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases. Journal of Infection 55:4, 347-352
CrossRef92
Joan Puig-Barberà, Javier Díez-Domingo, Ángel Belenguer Varea, Germán Schwarz Chavarri, José A. Lluch Rodrigo, Santiago Pérez Hoyos, David González Vidal. (2007) Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25:42, 7313-7321
CrossRef93
Sae Yoon Kee, Jin Soo Lee, Hee Jin Cheong, Byung Chul Chun, Joon Young Song, Won Suk Choi, Yu Mi Jo, Yoo Bin Seo, Woo Joo Kim. (2007) Influenza vaccine coverage rates and perceptions on vaccination in South Korea. Journal of Infection 55:3, 273-281
CrossRef94
Shu-Ling Hoshi, Masahide Kondo, Yasushi Honda, Ichiro Okubo. (2007) Cost–effectiveness analysis of influenza vaccination for people aged 65 and over in Japan. Vaccine 25:35, 6511-6521
CrossRef95
Kevin High. (2007) Immunizations in Older Adults. Clinics in Geriatric Medicine 23:3, 669-685
CrossRef96
Joseph M. Mylotte. (2007) Nursing Home–Associated Pneumonia. Clinics in Geriatric Medicine 23:3, 553-565
CrossRef97
Susan M Loughlin, Ali Mortazavi, Kevin W Garey, Gary K Rice, Kim K Birtcher. (2007) Pharmacist-Managed Vaccination Program Increased Influenza Vaccination Rates in Cardiovascular Patients Enrolled in a Secondary Prevention Lipid Clinic. Pharmacotherapy 27:5, 729-733
CrossRef98
Yi-Wen Tsai, Weng-Foung Huang, Yu-Wen Wen, Pei-Fen Chen. (2007) The Relationship between Influenza Vaccination and Outpatient Visits for Upper Respiratory Infection by the Elderly in Taiwan. Value in Health 10:2, 117-127
CrossRef99
L. A. Mandell, R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, D. M. Musher, M. S. Niederman, A. Torres, C. G. Whitney. (2007) Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases 44:Supplement 2, S27-S72
CrossRef100
Jean-Jacques Parienti, Fabrice Carrat. (2007) Viral pneumonia and respiratory sepsis: Association, causation, or it depends?*. Critical Care Medicine 35:2, 639-640
CrossRef101
Boyd H. Gilman, Arthur J. Bonito, Celia Eicheldinger. (2007) Impact of Influenza Immunization on Medical Expenditures Among Medicare Elderly, 1999–2003. American Journal of Preventive Medicine 32:2, 107-115
CrossRef102
Silvia Vázquez-Fernández del Pozo, Valentín Hernández-Barrera, Pilar Carrasco-Garrido, Ángel Gil de Miguel, Rodrigo Jiménez-García. (2007) Cambios en las coberturas vacunales antigripales en España entre los años 2001 y 2003. Análisis por comunidades autónomas. Gaceta Sanitaria 21:1, 10-17
CrossRef103
Chong-Shan Wang, Shan-Tair Wang, Ching-Te Lai, Li-Jen Lin, Pesus Chou. (2007) Impact of influenza vaccination on major cause-specific mortality. Vaccine 25:7, 1196-1203
CrossRef104
Frederick Palm, Armin Grau. (2007) Infection as a risk factor for stroke. Future Neurology 2:1, 59-71
CrossRef105
Gregory B. Seymann. (2006) Community-acquired pneumonia: Defining quality care. Journal of Hospital Medicine 1:6, 344-353
CrossRef106
A.M. Iorio, B. Camilloni, M. Basileo, F. Guercini, S. Conti, F. Ferrante, E. Paccamiccio, S. Iaboni, M. Vecchioli, A. Iorio. (2006) Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine 24:44-46, 6624-6628
CrossRef107
Francesco Landi, Graziano Onder, Matteo Cesari, Andrea Russo, Christian Barillaro, Roberto Bernabei. (2006) In a prospective observational study, influenza vaccination prevented hospitalization among older home care patients. Journal of Clinical Epidemiology 59:10, 1072-1077
CrossRef108
Ghinwa Dumyati. 2006. Influenza and Other Respiratory Viruses. , 191-214.
CrossRef109
Christoph Lichy, Armin J Grau. (2006) Investigating the association between influenza vaccination and reduced stroke risk. Expert Review of Vaccines 5:4, 535-540
CrossRef110
David M Mannino, Victor A Kiri. (2006) Changing the burden of COPD mortality. International Journal of COPD 1:3, 219-233
CrossRef111
Joshua M. Thorpe, Betsy L. Sleath, Carolyn T. Kalinowski Thorpe, Courtney H. Van Houtven, Susan J. Blalock, Lawrence R. Landerman, William H. Campbell, Elizabeth C. Clipp. (2006) Caregiver Psychological Distress as a Barrier to Influenza Vaccination Among Community-Dwelling Elderly With Dementia. Medical Care 44:8, 713-721
CrossRef112
Daniela Rivetti, Tom Jefferson, Roger E Thomas, Melanie Rudin, Alessandro Rivetti, Carlo Di Pietrantonj, Vittorio Demicheli, Daniela Rivetti. 2006. Vaccines for preventing influenza in the elderly. .
CrossRef113
Gabriel Chodick, Anthony D. Heymann, Manfred S. Green, Ehud Kokia, Varda Shalev. (2006) Late influenza vaccination is associated with reduced effectiveness. Preventive Medicine 43:1, 71-76
CrossRef114
Megumi Hara, Tatsuhiko Sakamoto, Keitaro Tanaka. (2006) Effectiveness of influenza vaccination in preventing influenza-like illness among community-dwelling elderly: Population-based cohort study in Japan. Vaccine 24:27-28, 5546-5551
CrossRef115
J. A. Linder, J. C. Chan, D. W. Bates. (2006) Appropriateness of antiviral prescribing for influenza in primary care: a retrospective analysis*. Journal of Clinical Pharmacy and Therapeutics 31:3, 245-252
CrossRef116
Rodrigo Jiménez-García, Valentín Hernández-Barrera, Pilar Carrasco Garrido, Silvia Vázquez-Fernández del Pozo, Ángel Gil de Miguel. (2006) Influenza vaccination among cardiovascular disease sufferers in Spain: Related factors and trend, 1993–2003. Vaccine 24:23, 5073-5082
CrossRef117
Gianluca Baio, Fabio Pammolli, Vincenzo Baldo, Renzo Trivello. (2006) Object-oriented influence diagram for cost–effectiveness analysis of influenza vaccination in the Italian elderly population. Expert Review of Pharmacoeconomics & Outcomes Research 6:3, 293-301
CrossRef118
Samir Malhotra, S F Paul Man, Don D Sin. (2006) Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs 11:2, 275-291
CrossRef119
Bradley A. Sharpe, Scott A. Flanders. (2006) Community-acquired pneumonia: A practical approach to management for the hospitalist. Journal of Hospital Medicine 1:3, 177-190
CrossRef120
Kendra L. Schwartz, Anne Victoria Neale, Justin Northrup, Joseph Monsur, Divya A. Patel, Rodrigo Tobar, Pascale M. Wortley. (2006) Racial Similarities in Response to Standardized Offer of Influenza Vaccination. A MetroNet Study. Journal of General Internal Medicine 21:4, 346-351
CrossRef121
Malina Schmidt-Ioanas, Hartmut Lode. (2006) Treatment of pneumonia in elderly patients. Expert Opinion on Pharmacotherapy 7:5, 499-507
CrossRef122
Michael Mair, Robert W. Grow, Julie Samia Mair, Lewis J. Radonovich. (2006) Universal Influenza Vaccination: The Time to Act Is Now. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 4:1, 20-40
CrossRef123
J. C. Virchow. (2006) COPD — zukünftige Therapieoptionen. Der Pneumologe 3:2, 129-139
CrossRef124
Michael Mair, Robert W. Grow, Julie Samia Mair, Lewis J. Radonovich. (2006) Universal Influenza Vaccination: The Time to Act Is Now. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science 0:0, 060224114020001
CrossRef125
A. R. Falsey, E. E. Walsh. (2006) Viral Pneumonia in Older Adults. Clinical Infectious Diseases 42:4, 518-524
CrossRef126
Armin J. Grau, Lars Marquardt, Christoph Lichy. (2006) The effect of infections and vaccinations on stroke risk. Expert Review of Neurotherapeutics 6:2, 175-183
CrossRef127
Chit Ming Wong, Lin Yang, King Pan Chan, Gabriel M. Leung, Kwok H. Chan, Yi Guan, Tai Hing Lam, Anthony Johnson Hedley, Joseph S. M. Peiris. (2006) Influenza-Associated Hospitalization in a Subtropical City. PLoS Medicine 3:4, e121
CrossRef128
Fabrice Carrat, Marianne Leruez-Ville, Marc Tonnellier, Jean-Luc Baudel, Juliette Deshayes, Pascal Meyer, Eric Maury, Julie Galimand, Christine Rouzioux, Georges Offenstadt. (2006) A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Medicine 32:1, 156-159
CrossRef129
H. Gil, P. Bailly, N. Meaux-Ruault, I. Clement, N. Floret, A. Guiot, C. Manteaux, D. Talon, N. Magy, J.L. Dupond. (2006) La vaccination antigrippale du personnel hospitalier. Enquête de prévalence au CHU de Besançon, hiver 2003–2004. La Revue de Médecine Interne 27:1, 5-9
CrossRef130
Mara Dinits-Pensy, Graeme N. Forrest, Alan S. Cross, Michael K. Hise. (2005) The Use of Vaccines in Adult Patients With Renal Disease. American Journal of Kidney Diseases 46:6, 997-1011
CrossRef131
Prediman K Shah, Kuang-Yuh Chyu, Gunilla N Fredrikson, Jan Nilsson. (2005) Immunomodulation of atherosclerosis with a vaccine. Nature Clinical Practice Cardiovascular Medicine 2:12, 639-646
CrossRef132
Roy A. Pleasants, Douglas Haden. (2005) An Update on Chronic Obstructive Pulmonary Disease. The Consultant Pharmacist 20:11, 965-975
CrossRef133
Gretchen N Neigh, Erica R Glasper, Staci D Bilbo, Richard J Traystman, A Courtney DeVries. (2005) Cardiac arrest/cardiopulmonary resuscitation augments cell-mediated immune function and transiently suppresses humoral immune function. Journal of Cerebral Blood Flow & Metabolism 25:11, 1424-1432
CrossRef134
J.S. Oxford, C. Manuguerra, O. Kistner, A. Linde, M. Kunze, W. Lange, B. Schweiger, G. Spala, H. Rebelo de Andrade, P.R. Pérez Breña, J. Beytout, L. Brydak, D. Caraffa de Stefano, O. Hungnes, J. Kyncl, E. Montomoli, A. Gil de Miguel, R. Vranckx, A. Osterhaus. (2005) A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. Vaccine 23:46-47, 5440-5449
CrossRef135
T Jefferson, D Rivetti, A Rivetti, M Rudin, C Di Pietrantonj, V Demicheli. (2005) Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. The Lancet 366:9492, 1165-1174
CrossRef136
T. Carels, J. Flamaing. (2005) Vaccinaties en ouderen: een update. Tijdschrift voor Gerontologie en Geriatrie 36:5, 225-231
CrossRef137
Eugene M. G. Milne. (2005) Mortality Spike at New Year but not Christmas in North East England. European Journal of Epidemiology 20:10, 849-854
CrossRef138
T. Ostbye, D. H. Taylor, W. S. Yancy, K. M. Krause. (2005) Associations Between Obesity and Receipt of Screening Mammography, Papanicolaou Tests, and Influenza Vaccination: Results from the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study. American Journal of Public Health 95:9, 1623-1630
CrossRef139
Janet E McElhaney, Kristin L Nichol. (2005) Influenza vaccines: crossing the translational gap to improve outcomes in the elderly. Aging Health 1:1, 167-177
CrossRef140
Jean-Paul Janssens. (2005) Pneumonia in the elderly (geriatric) population. Current Opinion in Internal Medicine 4:4, 405-409
CrossRef141
Anke Huckriede, Laura Bungener, Toon Stegmann, Toos Daemen, Jeroen Medema, Abraham M. Palache, Jan Wilschut. (2005) The virosome concept for influenza vaccines. Vaccine 23, S26-S38
CrossRef142
Janet E. McElhaney. (2005) The unmet need in the elderly: Designing new influenza vaccines for older adults. Vaccine 23, S10-S25
CrossRef143
I.A. de Bruijn, J. Nauta, W.C.M. Cramer, L. Gerez, A.M. Palache. (2005) Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23, S39-S49
CrossRef144
J.M. Saponi Cortes, J.F. Sánchez Muñoz-Torrero, T. Sánchez Sánchez, A. Costo Campoamor. (2005) Utilización y eficacia de la vacunación antigripal en la prevención de ingresos hospitalarios por descompensación cardiorrespiratoria en pacientes de alto riesgo en Cáceres (réplica). Revista Clínica Española 205:6, 302-303
CrossRef145
Helene Lupatkin. (2005) Influenza vaccine in the elderly and chronic obstructive pulmonary disease. Current Infectious Disease Reports 7:3, 200-203
CrossRef146
Armin J. Grau. (2005) Role of anti-infective strategies in the prevention of stroke. Current Treatment Options in Cardiovascular Medicine 7:3, 187-195
CrossRef147
Michael J. Schull, Muhammad M. Mamdani, Jiming Fang. (2005) Influenza and Emergency Department Utilization by Elders. Academic Emergency Medicine 12:4, 338-344
CrossRef148
Michael Rothberg. (2005) Cost-effective approaches to influenza prevention and treatment. Expert Review of Pharmacoeconomics & Outcomes Research 5:2, 141-152
CrossRef149
Kevin Fiscella. (2005) Commentary-Anatomy of Racial Disparity in Influenza Vaccination. Health Services Research 40:2, 539-550
CrossRef150
Andrew F. Shorr. (2005) Preventing Pneumonia: The Role for Pneumococcal and Influenza Vaccines. Clinics in Chest Medicine 26:1, 123-134
CrossRef151
Sen-Te Wang, Long-Teng Lee, Li-Sheng Chen, Tony Hsiu-Hsi Chen. (2005) Economic evaluation of vaccination against influenza in the elderly: an experience from a population-based influenza vaccination program in Taiwan. Vaccine 23:16, 1973-1980
CrossRef152
Stephen B. Osmon, Marin H. Kollef. (2005) Prevention of Pneumonia in the Hospital Setting. Clinics in Chest Medicine 26:1, 135-142
CrossRef153
H. Schwarz Chávarri, J.L. Ortuño López, A. Lattur Vílchez, V. Pedrera Carbonell, D. Orozco Beltrán, V. Gil Guillén. (2005) ¿Podemos mejorar las tasas de vacunación antigripal en los ancianos con enfermedades crónicas?. Atención Primaria 35:4, 178-183
CrossRef154
(2005) Australian Society for Geriatric Medicine Position Statement No. 7 Immunisation of Older People Revised 2004. Australasian Journal on Ageing 24:1, 47-52
CrossRef155
Peter W. Horby, Alison Williams, Margaret A. Burgess, Han Wang. (2005) Prevalence and determinants of influenza vaccination in Australians aged 40 years and over - a national survey. Australian and New Zealand Journal of Public Health 29:1, 35-37
CrossRef156
M. G. Ison, V. Campbell, C. Rembold, J. Dent, F. G. Hayden. (2005) Cardiac Findings during Uncomplicated Acute Influenza in Ambulatory Adults. Clinical Infectious Diseases 40:3, 415-422
CrossRef157
Ruth Kandel, Kevan L Hartshorn. (2005) Novel strategies for prevention and treatment of influenza. Expert Opinion on Therapeutic Targets 9:1, 1-22
CrossRef158
Wafik Farah Andrawes, Caroline Bussy, Jo??l Belmin. (2005) Prevention of Cardiovascular Events in Elderly People. Drugs & Aging 22:10, 859-876
CrossRef159
Kristin L Nichol. (2005) Influenza Vaccination in the Elderly. Drugs & Aging 22:6, 495-515
CrossRef160
Mohammad Madjid, Imran Awan, Muzammil Ali, Lorraine Frazier, Ward Casscells. (2005) Influenza and atherosclerosis: vaccination for cardiovascular disease prevention. Expert Opinion on Biological Therapy 5:1, 91-96
CrossRef161
Cynthia G. Whitney, Scott A. Harper. (2004) Lower respiratory tract infections: prevention using vaccines. Infectious Disease Clinics of North America 18:4, 899-917
CrossRef162
Chit‐Ming Wong, King‐Pan Chan, Anthony Johnson Hedley, J. S. Malik Peiris. (2004) Influenza‐Associated Mortality in Hong Kong. Clinical Infectious Diseases 39:11, 1611-1617
CrossRef163
Joan Puig-Barberà, Javier Diez-Domingo, Santiago Pérez Hoyos, Ángel Belenguer Varea, David González Vidal. (2004) Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23:3, 283-289
CrossRef164
Chong‐Shan Wang, Shan‐Tair Wang, Ching‐Te Lai, Li‐Jen Lin, Chien‐Ting Lee, Pesus Chou. (2004) Reducing Major Cause–Specific Hospitalization Rates and Shortening Hospital Stays after Influenza Vaccination. Clinical Infectious Diseases 39:11, 1604-1610
CrossRef165
Stephen Allsup, Alan Haycox, Martyn Regan, Margot Gosney. (2004) Is influenza vaccination cost effective for healthy people between ages 65 and 74 years?. Vaccine 23:5, 639-645
CrossRef166
Prediman K Shah, Kuang-Yuh Chyu, Gunilla N Fredrikson, Jan Nilsson. (2004) Vaccination for atherosclerosis: a novel therapeutic paradigm. Expert Review of Vaccines 3:6, 711-716
CrossRef167
T. R. Frieden. (2004) Asleep at the Switch: Local Public Health and Chronic Disease. American Journal of Public Health 94:12, 2059-2061
CrossRef168
Barbara W. Trautner, Robert L. Atmar, Amy Hulstrom, Rabih O. Darouiche. (2004) Inactivated influenza vaccination for people with spinal cord injury. Archives of Physical Medicine and Rehabilitation 85:11, 1886-1889
CrossRef169
Michael F. Parry, Brenda Grant, Anthony Iton, Patricia D. Parry, Diane Baranowsky. (2004) Influenza Vaccination: A Collaborative Effort to Improve the Health of the Community • . Infection Control and Hospital Epidemiology 25:11, 929-932
CrossRef170
TT Keller, ATA Mairuhu, DPM Brandjes, M Levi, Tymen Keller. 2004. Influenza vaccination to prevent myocardial infarction. .
CrossRef171
Wency W Ho, Elsie Hui, Timothy Kwok, Jean Woo. (2004) An outbreak of Severe Acute Respiratory Syndrome in a nursing home: Lessons to learn. Geriatrics and Gerontology International 4:s1, S186-S189
CrossRef172
Florence H.Y. Yap, Pak-Leung Ho, Kwok-Fai Lam, Paul K.S. Chan, Yeung-Hung Cheng, Joseph S.M. Peiris. (2004) Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. Journal of Medical Virology 73:4, 617-623
CrossRef173
R Handa, S Teo, R Booy. (2004) Influenza: current evidence and informed predictions. Expert Review of Vaccines 3:4, 443-451
CrossRef174
M.A.J.B Tacken, J.C.C Braspenning, A Berende, E Hak, D.H de Bakker, P.P Groenewegen, R.P.T.M Grol. (2004) Vaccination of high-risk patients against influenza: impact on primary care contact rates during epidemics. Vaccine 22:23-24, 2985-2992
CrossRef175
Yeong-Hwang Chen, Saou-Hsing Liou, Chih-Chieh Chou, Wen-Lin Su, Ching-Hui Loh, Shih-Ha Lin. (2004) Influenza and pneumococcal vaccination of the elderly in Taiwan. Vaccine 22:21-22, 2806-2811
CrossRef176
Sutherland, E. Rand, Cherniack, Reuben M., . (2004) Management of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 350:26, 2689-2697
Full Text177
Heath Kelly, John Attia, Ross Andrews, Richard F. Heller. (2004) The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 22:17-18, 2192-2198
CrossRef178
Marin H. Kollef. (2004) Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical Care Medicine 32:6, 1396-1405
CrossRef179
Ru-Chien Chi, Kathleen M. Neuzil. (2004) The Association of Sociodemographic Factors and Patient Attitudes on Influenza Vaccination Rates in Older Persons. The American Journal of the Medical Sciences 327:3, 113-117
CrossRef180
Janet E. McElhaney, John M. Herre, M.Louise Lawson, Sharon K. Cole, Bonnie L. Burke, Jonathan W. Hooton. (2004) Effect of congestive heart failure on humoral and ex vivo cellular immune responses to influenza vaccination in older adults. Vaccine 22:5-6, 682-689
CrossRef181
Yi-Hung Liu, Li-Min Huang, Jung-Der Wang. (2004) Reduction of Acute Respiratory Illness (ARI) due to a Voluntary Workplace Influenza Vaccination Program: Who are More Likely to Get the Benefit?. Journal of Occupational Health 46:6, 455-460
CrossRef182
L. A. Mandell, J. G. Bartlett, S. F. Dowell, T. M. File, D. M. Musher, C. Whitney. (2003) Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clinical Infectious Diseases 37:11, 1405-1433
CrossRef183
(2003) Anti-Aging Medicine LiteratureWatch. Journal of Anti-Aging Medicine 6:2, 149-167
CrossRef184
Alicia L. Wolfert, Jeanne Rozwadowski. (2003) Adult Immunizations: An Update. Primary Care Case Reviews 6:3, 134-141
CrossRef185
David Lieberman, Devora Lieberman. (2003) Management of respiratory infections in the elderly. Expert Review of Anti-infective Therapy 1:3, 505-516
CrossRef186
Felix A. Sarubbi. (2003) Introduction. Southern Medical Journal 96:8, 734
CrossRef187
Prescott P. Lee. (2003) Prevention and Control of Influenza. Southern Medical Journal 96:8, 751-757
CrossRef188
(2003) Care after Coronary-Artery Bypass Surgery. New England Journal of Medicine 349:3, 307-307
Full Text189
David G Meyers. (2003) Could Influenza Vaccination Prevent Myocardial Infarction, Stroke and Sudden Cardiac Death?. American Journal of Cardiovascular Drugs 3:4, 241-244
CrossRef190
Todd Gilmer, Patrick J O???Connor. (2003) Cost Effectiveness of Diabetes Mellitus Management Programs. Disease Management & Health Outcomes 11:7, 439-453
CrossRef
